Notice of Interim Results
Arecor Therapeutics PLC will release its interim results for the six months ending June 30, 2025, on Thursday, September 25, 2025. A webcast for analysts and institutional investors will be hosted by the Chief Executive Officer and Chief Financial Officer at 3pm UK time on the same day. The company's lead product is AT278, an ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides targeting the obesity and diabetes markets. The company is listed on AIM (AIM: AREC).
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
Cambridge, UK, 24 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, will announce its interim results for the six months ended 30 June on Thursday 25 September 2025.
Dr Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will host a webcast for analysts and institutional investors at 3pm UK time on Thursday 25 September 2025. To register, please contact arecor@vigoconsulting.com. A copy of the interim results presentation will be released after the meeting on the Company website at www.arecor.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.